The DESTINY-Breast08 is a large trial that investigates dose-finding, dose-expansion, safety, tolerability, pharmacokinetics and anti-tumour activity of T-DXd in combination with multiple other anti-cancer agents including chemotherapy, immunochemotherapy, AKT inhibitors, and other drugs among metastatic HER2-low breast cancer cases, including TNBC patients (NCT04556773) [26]. Here, ERBB2 is linked to breast carcinoma.